Terms: = Bone cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1
27 results:
1. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.
Abla O; Ries RE; Triche T; Gerbing RB; Hirsch B; Raimondi S; Cooper T; Farrar JE; Buteyn N; Harmon LM; Wen H; Deshpande AJ; Kolb EA; Gamis AS; Aplenc R; Alonzo T; Meshinchi S
Blood Adv; 2024 Apr; 8(8):2005-2017. PubMed ID: 38306602
[TBL] [Abstract] [Full Text] [Related]
2. Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis.
Camilli S; Lockey R; Kolliputi N
Cell Biochem Biophys; 2023 Sep; 81(3):421-426. PubMed ID: 37126200
[TBL] [Abstract] [Full Text] [Related]
3. Ribosomal proteins as distinct "passengers" of microvesicles: new semantics in myeloma and mesenchymal stem cells' communication.
Dabbah M; Lishner M; Jarchowsky-Dolberg O; Tartakover-Matalon S; Brin YS; Pasmanik-Chor M; Neumann A; Drucker L
Transl Res; 2021 Oct; 236():117-132. PubMed ID: 33887527
[TBL] [Abstract] [Full Text] [Related]
4. Selinexor decreases HIF-1α via inhibition of crm1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.
von Fallois M; Kosyna FK; Mandl M; Landesman Y; Dunst J; Depping R
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2025-2033. PubMed ID: 33856525
[TBL] [Abstract] [Full Text] [Related]
5. Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.
Machnicki MM; Górniak P; Pępek M; Szymczyk A; Iskierka-Jażdżewska E; Steckiewicz P; Bluszcz A; Rydzanicz M; Hus M; Płoski R; Makuch-Łasica H; Nowak G; Juszczyński P; Jamroziak K; Stokłosa T; Puła B
Eur J Haematol; 2021 Mar; 106(3):320-326. PubMed ID: 33190294
[TBL] [Abstract] [Full Text] [Related]
6. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
Theodoropoulos N; Lancman G; Chari A
Target Oncol; 2020 Dec; 15(6):697-708. PubMed ID: 33074469
[TBL] [Abstract] [Full Text] [Related]
7. p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma.
Currier AW; Kolb EA; Gorlick RG; Roth ME; Gopalakrishnan V; Sampson VB
Sci Rep; 2019 Apr; 9(1):6161. PubMed ID: 30992462
[TBL] [Abstract] [Full Text] [Related]
8. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.
Hu B; Patel KP; Chen HC; Wang X; Wang F; Luthra R; Routbort MJ; Kanagal-Shamanna R; Medeiros LJ; Yin CC; Zuo Z; Ok CY; Loghavi S; Tang G; Tambaro FP; Thompson P; Burger J; Jain N; Ferrajoli A; Bose P; Estrov Z; Keating MJ; Wierda WG
Br J Haematol; 2019 Jun; 185(5):852-864. PubMed ID: 30924136
[TBL] [Abstract] [Full Text] [Related]
9. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Garzon R; Savona M; Baz R; Andreeff M; Gabrail N; Gutierrez M; Savoie L; Mau-Sorensen PM; Wagner-Johnston N; Yee K; Unger TJ; Saint-Martin JR; Carlson R; Rashal T; Kashyap T; Klebanov B; Shacham S; Kauffman M; Stone R
Blood; 2017 Jun; 129(24):3165-3174. PubMed ID: 28336527
[TBL] [Abstract] [Full Text] [Related]
10. Clinical and molecular characteristics of xpo1 mutations in patients with chronic lymphocytic leukemia.
Jain P; Kanagal-Shamanna R; Wierda W; Keating M; Sarwari N; Rozovski U; Thompson P; Burger J; Kantarjian H; Patel KP; Medeiros LJ; Luthra R; Estrov Z
Am J Hematol; 2016 Nov; 91(11):E478-E479. PubMed ID: 27468087
[TBL] [Abstract] [Full Text] [Related]
11. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract] [Full Text] [Related]
12. Treatment of acquired drug resistance in multiple myeloma by combination therapy with xpo1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract] [Full Text] [Related]
13. crm1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract] [Full Text] [Related]
14. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract] [Full Text] [Related]
15. Preclinical activity of selinexor, an inhibitor of xpo1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract] [Full Text] [Related]
16. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
Gravina GL; Mancini A; Sanita P; Vitale F; Marampon F; Ventura L; Landesman Y; McCauley D; Kauffman M; Shacham S; Festuccia C
BMC Cancer; 2015 Dec; 15():941. PubMed ID: 26620414
[TBL] [Abstract] [Full Text] [Related]
17. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.
Niu M; Xu X; Shen Y; Yao Y; Qiao J; Zhu F; Zeng L; Liu X; Xu K
Chem Biol Interact; 2015 Jul; 237():66-72. PubMed ID: 26026911
[TBL] [Abstract] [Full Text] [Related]
18. Novel reversible selective inhibitor of nuclear export shows that crm1 is a target in colorectal cancer cells.
Niu M; Chong Y; Han Y; Liu X
Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
[TBL] [Abstract] [Full Text] [Related]
19. xpo1/crm1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract] [Full Text] [Related]
20. Preclinical and clinical efficacy of xpo1/crm1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
[TBL] [Abstract] [Full Text] [Related]
[Next]
